mAbxience to Produce AstraZeneca’s COVID-19 Vaccine for Latin America

AstraZeneca has entered into an agreement with mAbxience of the INSUD Group to produce AZ’s COVID-19 vaccine for most of Latin America from manufacturing facilities in Mexico and Argentina.

The deal between the UK-based drugmaker and Spain-based mAbxience provides for an initial production of 150 million doses, which could be extended to up to 250 million doses. Deliveries are expected to begin in the first half of 2021, provided the vaccine is approved.

The deal does not apply to Brazil, where AstraZeneca has entered into a separate supply agreement.